The shadow of generic challenges has long loomed above copyright’s iconic drug, Sildenafil, triggering questions about the outlook of similar medicinal stakes. While first periods saw substantial returns, the exclusivity end has created the door for discounted alternatives, potentially diminishing earnings and presenting a real hazard for shareho